Pacira BioSciences, Inc. (NASDAQ:PCRX) Shares Bought by SG Americas Securities LLC

SG Americas Securities LLC raised its position in Pacira BioSciences, Inc. (NASDAQ:PCRX) by 96.4% in the third quarter, according to its most recent Form 13F filing with the SEC. The institutional investor owned 25,254 shares of the company’s stock after buying an additional 12,396 shares during the period. SG Americas Securities LLC owned about 0.05% of Pacira BioSciences worth $380,000 at the end of the most recent quarter.

A number of other large investors have also modified their holdings of the company. Vanguard Group Inc. raised its stake in shares of Pacira BioSciences by 0.3% during the 1st quarter. Vanguard Group Inc. now owns 5,113,384 shares of the company’s stock worth $149,413,000 after buying an additional 14,960 shares during the period. Pacer Advisors Inc. lifted its holdings in Pacira BioSciences by 37.5% during the second quarter. Pacer Advisors Inc. now owns 2,162,787 shares of the company’s stock valued at $61,877,000 after purchasing an additional 590,082 shares in the last quarter. Renaissance Technologies LLC lifted its holdings in Pacira BioSciences by 9.8% during the second quarter. Renaissance Technologies LLC now owns 2,066,197 shares of the company’s stock valued at $59,114,000 after purchasing an additional 184,000 shares in the last quarter. Dimensional Fund Advisors LP grew its position in shares of Pacira BioSciences by 12.2% in the second quarter. Dimensional Fund Advisors LP now owns 1,828,065 shares of the company’s stock valued at $52,300,000 after purchasing an additional 198,936 shares during the period. Finally, Clearbridge Investments LLC increased its stake in shares of Pacira BioSciences by 2.3% during the first quarter. Clearbridge Investments LLC now owns 1,172,150 shares of the company’s stock worth $34,250,000 after purchasing an additional 26,463 shares in the last quarter. Institutional investors and hedge funds own 99.73% of the company’s stock.

Pacira BioSciences Trading Up 3.2 %

Shares of PCRX opened at $17.49 on Friday. Pacira BioSciences, Inc. has a 12-month low of $11.16 and a 12-month high of $35.95. The firm has a market capitalization of $806.81 million, a P/E ratio of 13.35 and a beta of 0.84. The firm has a 50-day moving average price of $14.64 and a 200 day moving average price of $22.08. The company has a current ratio of 6.82, a quick ratio of 5.70 and a debt-to-equity ratio of 0.67.

Pacira BioSciences (NASDAQ:PCRX) last posted its quarterly earnings results on Tuesday, July 30th. The company reported $0.64 earnings per share for the quarter, beating the consensus estimate of $0.53 by $0.11. The business had revenue of $178.02 million during the quarter, compared to analysts’ expectations of $173.31 million. Pacira BioSciences had a net margin of 9.21% and a return on equity of 13.22%. Sell-side analysts forecast that Pacira BioSciences, Inc. will post 2.24 EPS for the current year.

Analysts Set New Price Targets

Several equities research analysts recently issued reports on PCRX shares. Raymond James cut Pacira BioSciences from an “outperform” rating to a “market perform” rating in a report on Monday, August 12th. Piper Sandler lowered Pacira BioSciences from an “overweight” rating to a “neutral” rating and lowered their price target for the stock from $42.00 to $11.00 in a research note on Monday, August 12th. JPMorgan Chase & Co. reissued an “underweight” rating and issued a $10.00 price objective (down from $45.00) on shares of Pacira BioSciences in a research note on Monday, August 12th. Truist Financial cut shares of Pacira BioSciences from a “buy” rating to a “sell” rating and lowered their target price for the stock from $30.00 to $8.00 in a research note on Tuesday, August 13th. Finally, Barclays cut shares of Pacira BioSciences from an “overweight” rating to an “equal weight” rating and reduced their target price for the company from $38.00 to $25.00 in a research report on Wednesday, July 3rd. Two investment analysts have rated the stock with a sell rating, four have issued a hold rating and five have given a buy rating to the company’s stock. According to MarketBeat.com, the company currently has an average rating of “Hold” and a consensus target price of $24.20.

Insiders Place Their Bets

In other Pacira BioSciences news, CEO Frank D. Lee purchased 8,264 shares of the stock in a transaction dated Monday, August 12th. The stock was acquired at an average cost of $12.10 per share, for a total transaction of $99,994.40. Following the acquisition, the chief executive officer now owns 107,784 shares in the company, valued at $1,304,186.40. This trade represents a 0.00 % increase in their position. The acquisition was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website. Insiders acquired a total of 11,176 shares of company stock valued at $136,240 over the last quarter. 6.40% of the stock is owned by insiders.

About Pacira BioSciences

Pacira BioSciences, Inc engages in the development, manufacture, marketing, distribution, and sale of non-opioid pain management and regenerative health solutions to healthcare practitioners in the United States. The company offers EXPAREL, a bupivacaine liposome injectable suspension; ZILRETTA, a triamcinolone acetonide extended-release injectable suspension; and iovera system, a non-opioid handheld cryoanalgesia device used to produce controlled doses of cold temperature to targeted nerves.